Clinical Trials - Open

The clinical trials listed in this section are open to patient recruitment. For each trial, an overview of the study design is provided together with a brief explanation of the trial objectives. Members can review the Trial Report in the Members Area.

Filter AGITG trials by

Multicentre non-interventional prospective cohort study to identify potential RNA and DNA-based risk factors associated with immune-related adverse events (irAEs) Read More

A Phase-1 single-blind study evaluating the safety and tolerability of adding LSTA1 to the combination of durvalumab, gemcitabine, and nab-paclitaxel in subjects with locally advanced pancreatic ductal adenocarcinomas. Read More

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma Read More

Multi-centre, prospective cohort study. This study will review the feasibility and potential benefit of instituting routine comprehensive molecular profiling of ABC using either fresh frozen or archival tissue obtained at the time of routine diagnostic tests such as percutaneous biopsy, ERCP or EUS. Read More

A phase II trial evaluating EGFR inhibition with HDAC inhibition in refractory colorectal cancer Read More

Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer Read More

Understanding the effect of chemotherapy on microbial composition of pancreatic ductal adenocarcinoma (PDAC) patients Read More

NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer Read More

A Randomised, double-blinded phase II study of gemcitabine and nab‐paclitaxel with CEND‐1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma Read More

A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) Read More

Radiological And subjective measures of Nutrition, Diet and sarcOpenia - a Masterplan Substudy (RANDOMS) Read More

This is an open-label, randomised, prospective, multi-centre registry-based trial evaluating the impact of delivering all active cytotoxic agents during initial systemic therapy, by way of an alternating treatment schedule versus standard of care, on outcomes in treatment-naïve mCRC. Read More

This Translational study aims to provide a second tier screening test to identify the patients at the highest risk of CRC to fast track their diagnosis. Read More

A translational substudy of NEO-IMPACT to investigate the longitudinal evolution of the pancreas cancer microbiome when exposed to chemo-immunotherapy pre-operatively. Read More

This translational study aims to determine what impact STING levels have on the ability for gastro-oesophageal cancers to respond to treatment, how this impacts the immune response to cancer and ultimately the ability to survive. Read More

PALliative oEsOphageal cancer chemoradioimmunotherapy (PALEO): A multicentre Phase II Clinical Trial Read More

Can Oxaliplatin dose reduction and neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer? A phase II randomised study. Read More

mFOLFIRINOX And STEreotactic body Radiotherapy (SBRT) for Pancreatic cancer with high-risk and Locally Advanced disease (MASTERPLAN): a multicentre, randomised phase II study. Read More

Prospective Study of ‘Watch and Wait’ Strategy in Patients with Rectal Cancer who have Developed a Clinical Complete Response with concurrent Chemo‐radiotherapy: RENO trial (REctal cancer No Operation) Read More

This randomised phase II trial aims to evaluate the effect of simvastatin (SIM) on efficacy and toxicity of pCRT in rectal cancer patients, and on systemic and local inflammatory responses. Read More